Navigation Links
SemBioSys signs option agreement for safflower-produced food ingredient
Date:1/29/2008

TSX symbol: SBS

CALGARY, Jan. 29 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has signed an option agreement with The Instituto de Agrobiotecnologia Rosario S.A. (INDEAR) based in Rosario, Argentina. INDEAR is a joint venture company formed by Bio Sidus AG S.A. and Bioceres S.A. to develop manufacturing and development capabilities for agricultural biotechnology products for South American markets. Under the terms of the agreement, INDEAR will evaluate the utility of using plant-produced chymosin for the production of cheese in South America. As per the agreement, SemBioSys will receive an option fee and will be eligible to collect an upfront license fee, possible milestone payments and royalties or other form of profit-sharing in the event INDEAR chooses to exercise their option.

"This agreement demonstrates the breadth of opportunity offered by our plant-based technology platform. The cost advantages of producing insulin and Apo AI in plants are also applicable to non-pharmaceutical products, in this case chymosin as a protein-based food processing agent," said Andrew Baum, President and CEO of SemBioSys. "Our work with chymosin is quite advanced and we believe that it offers compelling economic advantages relative to traditional sources of chymosin enzyme. We are excited at the prospect of working with INDEAR to bring this product to market in South America, subject to INDEAR's successful completion of their evaluation.

Chymosin, also called rennet, is a natural enzyme used in the production of cheese obtained originally from calve stomachs. The majority of chymosin used today is produced via fermentation. Using its proprietary plant expression system, SemBioSys has developed safflower-produced chymosin and an extraction process that it believes will allow for the production of chymosin in plants at significantly lower costs.

About SemBioSys Genetics Inc. (http://www.sembiosys.com)

Calgary, Alberta-based SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates, produced in the plant host safflower, are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing human topical, nutritional oils and animal health markets.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at http://www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys announces 2007 third quarter results
2. SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting
3. SemBioSys updates Apo AI development program
4. AMDL Signs 100 Strategic Cooperation Agreements in China for Its JPGreen Clinics; Gross Sales Per Each Location Could Exceed $400,000
5. Protalix BioTherapeutics Signs Lease Agreement for Expansion of its Manufacturing and Research Facility in Carmiel, Israel
6. University of Maryland, Baltimore BioPark Signs Gliknik Inc. as First Tenant in Its BioInnovation Center in Building Two
7. Amic Signs Non-Exclusive License Agreement With Roche Diagnostics for Key Cardiac Marker NT-proBNP
8. Kiwa Signs Letter of Intent with Huaxing Animal Medicine
9. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
10. Pharsight Signs Third WinNonlin(R) AutoPilot(TM) Customer
11. Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... Biodex Medical ... and ambulation aid in one device. This assistive aid lifts patients safely from a ... harness and motorized lift mechanics. The Mobility Assist is the latest in a line ...
(Date:6/26/2017)... VIRGINIA (PRWEB) , ... June 26, 2017 , ... ... today that Melissa Kirkegaard, the former Associate Director of Product Development R&D at ... biological and pharmaceutical products at both start-up and established biopharma companies, has joined ...
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in water ... Board of Directors. Dr. Henig will bring a wealth of scientific experience in the ... the Chief Technical and Scientific Officer of four major global companies in the last ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Academy of Model ... University Aviation Association (UAA), the unifying voice for collegiate aviation education, are launching ... teamwork, competition, and success through a STEM-based education platform. , Much like the ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 According to a ... Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, Deployment ... the IAM Market is expected to grow from USD 14.30 Billion in ... Rate (CAGR) of 17.3%. ... MarketsandMarkets Logo ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
Breaking Biology News(10 mins):